Eisai Limited
Clinical trials sponsored by Eisai Limited, explained in plain language.
Pharmaceutical company focused on neurology and oncology (subsidiary of Eisai).
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Can Real-World data reveal hidden risks of an Alzheimer's drug?
Knowledge-focused Not yet recruitingThis study is a registry that follows 400 people with Alzheimer's disease who have been prescribed LEQEMBI in routine clinical practice. The goal is to track how often and how severely certain side effects occur, including brain swelling (ARIA-E), small brain bleeds (ARIA-H), lar…
Sponsor: Eisai Limited • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Can Real-World data uncover hidden risks of the Alzheimer's drug LEQEMBI?
Knowledge-focused Not yet recruitingThis registry study follows 400 Alzheimer's patients in Canada who are prescribed LEQEMBI, a medication for the disease. The goal is to track the frequency and severity of known side effects, such as brain swelling (ARIA-E), microbleeds (ARIA-H), and larger brain hemorrhages, dur…
Sponsor: Eisai Limited • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC